14
Participants
Start Date
August 31, 2009
Primary Completion Date
January 31, 2010
Study Completion Date
March 31, 2011
Cediranib
Given orally at a dose of 20mg/day everyday until the patient meets any discontinuation criterion.
Cisplatin
Given as a intravenous infusion at a dose of 80mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
S-1
Given orally at a dose of 80 - 120mg/day according to BSA for 3 weeks followed by a 2-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
Cisplatin
60mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
Capecitabine
Given orally at a dose of 1000mg/m2 twice daily for 2 weeks followed by a 1-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
Research Site, Nagoya
Research Site, Sayama
Research Site, Sunto-gun
Research Site, Chūō
Lead Sponsor
AstraZeneca
INDUSTRY